Recent U.S.–India trade relations developments have stirred discussions across global markets. The United States’ announcement of a 90-day pause on reciprocal tariffs signals caution and cooperation. While a 10% baseline tariff remains in effect, the temporary suspension offers space for negotiations. For Indian exporters, this period presents both challenges and critical opportunities for strategic realignment. Understanding the Tariff Pause and Its Immediate Implications On April 9, 2025, the U.S. administration declared a 90-day delay in implementing the 26% reciprocal tariff on Indian imports. However, the 10% baseline tariff introduced on April 5 applies to all countries, including India. The 90-day US tariff pause offers a crucial window for India to initiate strategic negotiations, with the objective of finalising a mutually beneficial agreement Reciprocal Tariff Suspension: India now has 90 days to negotiate a trade framework that could permanently remove or reduce the proposed 26% duty. Baseline Tariff Continues: All countries’ standard 10% import tariff remains in effect. This could marginally impact pricing but allows time for exporters to adjust. Negotiation Opportunity: Both nations are actively engaging in developing a multi-sectoral Bilateral Trade Agreement (BTA). The aim is to reduce trade barriers and enhance cooperation. The tariff suspension allows Indian industries to regroup and strategise their next moves while maintaining current export levels. Impact on India’s Electronics Sector India’s electronics sector is one of the biggest beneficiaries of the tariff pause. Exemptions granted to this industry offer it a competitive edge, especially against other Asian markets. Electronics exports have surged, and this momentum could translate into long-term gains. Electronics Products Under Tariff Exemption The U.S. has excluded several consumer and industrial electronics from the 26% tariff proposal. These products now enjoy temporary zero-duty status. Consumer Electronics: Smartphones, PCs, laptops, hard drives, processors, and memory chips are exempt. These items form the core of India’s electronics exports. Industrial Electronics: Semiconductor machines, communication tools, solar cells, flat-panel displays, and AI servers are exempted. This reduces cost barriers for large-scale Indian manufacturers. Strategic Classification: The electronics category is expected to fall under a broader semiconductor-specific industry bracket. This could ensure long-term exemptions and incentives. India’s Export Performance in Electronics The industry is rapidly growing, primarily fueled by government support and global demand. Export Growth: India’s electronics exports reached US$22.5 billion in the first eight months of FY 2024–25. This marks a 28% rise over the same period in FY 2023–24. Smartphone Surge: Smartphone exports alone hit US$13.11 billion, up 45% from US$9.07 billion in the previous year. This accounts for 58% of total electronics exports. PLI Scheme Impact: The Production Linked Incentive (PLI) scheme has been instrumental. It has encouraged global tech firms to ramp up production in India. Strategic Opportunity for India India’s electronics sector is at a turning point. Continued tariff exemptions could fuel long-term growth and investment. Tariff Edge over China: India enjoys a 20% tariff advantage over China. This gives it a strong edge in attracting global supply chains. Global Expansion: Companies like Apple are now scaling up operations in India. This could make India a central hub for global tech manufacturing. Domestic Value Addition: The government is focused on doubling value addition in electronics manufacturing. This will strengthen India’s position vis-à-vis South-East Asian economies. The tariff pause, if extended, could cement India’s place as a leading electronics exporter. Impact on the Pharmaceutical Sector While the initial 10% tariff excluded pharmaceuticals, the landscape is changing. New developments suggest growing pressure on India’s pharma exports to the U.S. The next phase of tariff implementation could include drugs and active pharmaceutical ingredients (APIs). Policy Shifts and Investigations The U.S. government is moving towards self-reliance in drug manufacturing. This has led to new investigations that may impact imports from India. Section 232 Investigation: Citing national security, the Trump administration has launched a review under Section 232 of the Trade Expansion Act to reduce the U.S. dependency on foreign pharmaceuticals. Future Tariff Risks: Although currently exempt, pharmaceuticals may soon face separate tariffs. This could disrupt the global supply chain and price structure. National Security Justification: The move places pharma in the same policy zone as steel and semiconductors. It could lead to broader regulatory action. India’s Pharma Export Landscape India is a critical supplier of generic medicines to the U.S. Any tariffs here could significantly affect revenues and market strategies. Export Volumes: India ranks third globally in pharmaceutical production by volume. It exports to nearly 200 countries, with the U.S. as the top destination. Generic Drug Dependence: Most exports consist of generics. Tariff hikes may challenge cost recovery and reduce profit margins. Short-Term Disruptions: Pharmaceutical companies may experience shipping delays and price fluctuations. Supply chain adjustments will be essential. Strategic Response and Outlook Indian pharma firms must act quickly to adapt to the evolving regulatory climate. Diversification Needed: Companies should look beyond the U.S. and explore Europe, Africa, and Southeast Asia. This will reduce their dependency on one market. Product Mix Shift: Focus on high-margin, niche pharmaceuticals can offset lower margins on generics. R&D investments will be crucial. FTA as a Path Forward: India is pursuing FTAs to stabilise trade conditions. These agreements could reduce future tariff risks and expand market access. In the short term, India must use the 90-day window to reinforce its trade position. Long-term competitiveness will depend on agility and innovation. MFN Drug Pricing Policy: A New Challenge for Indian Pharma The U.S. government’s “Most Favoured Nation” drug pricing policy could reshape global pharmaceutical pricing dynamics. For India, this means tighter profit margins and market pressures. The policy aims to align U.S. drug prices with those in the lowest-cost countries. Profitability Impact: Indian pharma firms may be forced to lower prices in the U.S. This could squeeze margins and limit R&D budgets. Global Price Shift: Companies might raise prices in other markets to maintain margins, which could impact patients in developing countries. Trade Strategy Shift: Indian firms must revise global pricing strategies. Balanced pricing will be key to sustaining global reach. The MFN policy adds urgency to diversify markets … Read more
